Drug Trial Radar · NCT01268358
Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
Last checked: Nov 20, 2026Latest source record: Aug 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Oct 2010
Primary completion
Jan 2011
Study completion Jan 2011
Sponsor
- Lead sponsor
- Zymenex A/SIndustry
- Sponsor type
- Industry
- Collaborators
- European Commission
- First posted
- Dec 30, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, open-label, dose escalation study of patients with alpha-mannosidosis. 10 patients will be enrolled in this study receiving intravenous infusions of Lamazym. In order to avoid development of delayed hypersensitivity all patients will continue weekly treatment at the designated dose until the Safety Committee approves transfer to the rhLAMAN-03 protocol. It is the hypothesis that Lamazym is safe to use.
Conditions
- Alpha Mannosidosis
Interventions
LamazymDrug
Lamazym, ERT, infusion weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety profile of rhLAMAN (Lamazym)Time frame: 1-5 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.